Zevra Therapeutics Holds Annual Stockholder Meeting
Ticker: ZVRA · Form: 8-K · Filed: May 13, 2024 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K |
| Filed Date | May 13, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: stockholder-meeting, governance, annual-meeting
TL;DR
Zevra shareholders voted on directors and auditors.
AI Summary
On May 13, 2024, Zevra Therapeutics, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders voted on several proposals, including the election of directors and the ratification of the appointment of its independent registered public accounting firm.
Why It Matters
This filing confirms the outcomes of key shareholder votes, providing clarity on the company's governance and financial oversight.
Risk Assessment
Risk Level: low — This is a routine filing reporting on the results of an annual stockholder meeting, with no new material financial or operational information.
Key Numbers
- 001-36913 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-5894398 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Zevra Therapeutics, Inc. (company) — Registrant
- May 13, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 (address) — Principal Executive Offices
- Kempharm, Inc. (company) — Former Company Name
FAQ
What was the primary purpose of this 8-K filing?
The primary purpose was to report the results of Zevra Therapeutics, Inc.'s annual meeting of stockholders held on May 13, 2024.
What specific items were voted on by the stockholders?
The filing indicates that stockholders voted on matters including the election of directors and the ratification of the appointment of the independent registered public accounting firm.
When was the report filed with the SEC?
The report was filed as of May 13, 2024.
What is Zevra Therapeutics, Inc.'s state of incorporation?
Zevra Therapeutics, Inc. is incorporated in Delaware.
What was the company's former name?
The company was formerly known as Kempharm, Inc.
Filing Stats: 769 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-05-13 16:47:06
Key Financial Figures
- $0.0001 — ch registered Common Stock , par value $0.0001 per share ZVRA The Nasdaq Stock Mark
Filing Documents
- zvra20240513_8k.htm (8-K) — 42KB
- 0001437749-24-016275.txt ( ) — 172KB
- zvra-20240513.xsd (EX-101.SCH) — 3KB
- zvra-20240513_def.xml (EX-101.DEF) — 11KB
- zvra-20240513_lab.xml (EX-101.LAB) — 15KB
- zvra-20240513_pre.xml (EX-101.PRE) — 11KB
- zvra20240513_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 13, 2024, Zevra Therapeutics, Inc. (the " Company ") held its 2024 Annual Meeting of Stockholders (the " 2024 Annual Meeting "), for the following purposes: to elect three Class III directors to the Company's board of directors to hold office until the 2027 annual meeting of stockholders; to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; to approve, on an advisory and non-binding basis, the compensation of the Company's named executive officers; and to approve amendments to the Company's Amended and Restated 2014 Equity Incentive Plan. Of the 41,850,494 shares outstanding as of the March 22, 2024 record date, at least 31,194,215 shares, or 74.54%, were present or represented by proxy at the 2024 Annual Meeting. At the 2024 Annual Meeting, each of Thomas D. Anderson, Neil F. McFarlane, and Alvin Shih, M.D. was elected as a director of the Company. Also at the 2024 Annual Meeting, the stockholders of the Company ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024, and approved, on an advisory and non-binding basis, the compensation of the Company's named executive officers. The stockholders of the Company did not approve the amendments to the Company's Amended and Restated 2014 Equity Incentive Plan. Based on tabulation and validation by Computershare, Inc., the independent inspector of election for the 2024 Annual Meeting, the final voting results on each of the matters submitted to a vote of stockholders at the 2024 Annual Meeting were as follows: 1. Election of Directors For Withheld Broker Non-Votes Thomas D. Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 Fo
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Zevra Therapeutics, Inc . Date: May 13, 2024 By: /s/ Timothy J. Sangiovanni Timothy J. Sangiovanni, CPA Senior Vice President, Corporate Controller